Identification of cell surface targets for HIV-1 therapeutics using genetic screens  by Dunn, Stephen J et al.
www.elsevier.com/locate/yviro
Virology 321 (2004) 260–273Identification of cell surface targets for HIV-1 therapeutics using
genetic screens
Stephen J. Dunn,a,* Imran H. Khan,b Ursula A. Chan,a Robin L. Scearce,a
Claudia L. Melara,a,1 Amber M. Paul,a,2 Vikram Sharma,a,3 Fong-Yih Bih,a
Tanya A. Holzmayer,a,4 Paul A. Luciw,b and Arie Aboa,*
aPPD Discovery, Inc., Menlo Park, CA 94025, USA
bCenter for Comparative Medicine, University of California, Davis, CA 95616, USAReceived 12 November 2003; returned to author for revision 17 December 2003; accepted 9 January 2004Abstract
Human immunodeficiency virus (HIV) drugs designed to interfere with obligatory utilization of certain host cell factors by virus are less
likely to encounter development of resistant strains than drugs directed against viral components. Several cellular genes required for
productive infection by HIV were identified by the use of genetic suppressor element (GSE) technology as potential targets for anti-HIV drug
development. Fragmented cDNA libraries from various pools of human peripheral blood mononuclear cells (PBMC) were expressed in vitro
in human immunodeficiency virus type 1 (HIV-1)-susceptible cell lines and subjected to genetic screens to identify GSEs that interfered with
viral replication. After three rounds of selection, more than 15000 GSEs were sequenced, and the cognate genes were identified. The GSEs
that inhibited the virus were derived from a diverse set of genes including cell surface receptors, cytokines, signaling proteins, transcription
factors, as well as genes with unknown function. Approximately 2.5% of the identified genes were previously shown to play a role in the
HIV-1 life cycle; this finding supports the biological relevance of the assay. GSEs were derived from the following 12 cell surface proteins:
CXCR4, CCR4, CCR7, CD11C, CD44, CD47, CD68, CD69, CD74, CSF3R, GABBR1, and TNFR2. Requirement of some of these genes
for viral infection was also investigated by using RNA interference (RNAi) technology; accordingly, 10 genes were implicated in early events
of the viral life cycle, before viral DNA synthesis. Thus, these cell surface proteins represent novel targets for the development of therapeutics
against HIV-1 infection and AIDS.
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Introduction surface proteins were previously identified to interact withThe complex life cycle of the human immunodeficiency
virus type 1 (HIV-1) involves multiple functional inter-
actions with host cell factors, several of which may serve
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4 Deceased.HIV-1 to facilitate and assist the virus in successfully
infecting cells, the co-receptors, CXCR4 and CCR5, along
with the viral attachment receptor CD4 are the most
extensively studied (reviewed in Berger et al., 1999;
Hoffman and Doms, 1998; Littman, 1998). Therapeutic
efforts are currently focused on developing inhibitors
against CCR5, CXCR4, and CD4 (reviewed in Agrawal
and Alkhatib, 2001; Moore and Stevenson, 2000). It is
clear that CD4 and the co-receptors are necessary for
efficient viral infection. It is less evident to what extent
other cell surface molecules might be involved in this
process. Roles for surface molecules in the early stage of
HIV-1 replication include enhancement of attachment
leading to efficient fusion of virion and cell membranes,
entry of virions into the cell cytoplasm, as well as
modulation of signal transduction pathways essential for
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2001, 2002; Davis et al., 1997; Hioe et al., 1998; Misse
et al., 1999; Ott, 2002; Stauber et al., 1999; Ugolini et al.,
1999).
Several cellular factors interacting with HIV-1 have been
previously identified using techniques that examined
RNA–protein, protein–protein interactions, or differential
RNA expression of infected cells (Ambrosino et al., 1997;
Cimarelli and Luban, 1999; Corbeil et al., 2001; de la
Fuente et al., 2002; Fukushi et al., 1999; Geiss et al., 2000;
Lama and Trono, 1998; Mahalingam et al., 1998; Rossi et
al., 1997; Ruhl et al., 1993; Ryo et al., 2000; Van’t Wout et
al., 2003; Venkatesh et al., 2003; Withers-Ward et al.,
1997). These techniques identify molecular complexes or
factors, but do not provide information about the functional
significance of the interaction for the viral life cycle.
Recently, RNA interference (RNAi) has been utilized to
functionally validate cellular genes involved in HIV-1
infection. To date, however, only CD4, CXCR4, CCR5
and a cellular gene involved in viral egress, Tsg101, have
been analyzed by this approach (Garrus et al., 2001;
Martinez et al., 2002; Novina et al., 2002; Surabhi and
Gaynor, 2002).
The GSX system involves a genetic method that identi-
fies functionally relevant genes through the selection of
genetic suppressor elements (GSEs). GSEs act by down-
modulating a target gene function through an inhibitory
RNA or transdominant peptide. This system was first used
to identify viral genes that are essential for the infectious
cycle of bacteriophage lambda (Holzmayer et al., 1992). In
addition, the GSX system was also used to identify novel
tumor suppressor genes, genes that mediate cellular sensi-
tivity to anticancer drugs, and to identify genetic inhibitors
of HIV-1 (Dunn et al., 1999; Gallagher et al., 1997;
Garkavtsev et al., 1996; Gudkov et al., 1993, 1994; Lev-
enson et al., 1999; Novoa et al., 2001; Ossovskaya et al.,
1996; Pestov and Lau, 1994; Primiano et al., 2003). GSE
screens enable simultaneous interrogation of large collec-
tions of genes to assign function to genes in cellular models.
Here, we describe a GSE screen designed to identify
functionally important cellular genes necessary for HIV-1
replication. This screen was previously used to isolate
genetic inhibitors of HIV-1 derived from the HIV-1 genome
(Dunn et al., 1999). By expanding this approach, a diverse
set of cellular targets essential for HIV replication was
identified. Further effort was focused on studying the role
of novel cell surface proteins in early events of the HIV-1
life cycle. Selected cell surface proteins were further tested
by using RNAi methodology for downmodulation of the
respective genes and inhibitory effect on HIV-1 replication.
The amount of viral DNA synthesis, measured postinfection
by real-time PCR, showed that 10 cellular genes played a
key role in viral replication at steps before viral DNA
synthesis. Thus, these cell surface proteins represent novel
targets for the development of therapeutics against HIV-1
infection and AIDS.Results
GSE screens to functionally identify genes involved in HIV-1
replication
To identify cellular genes that are implicated in HIV-1
replication, multiple GSE libraries derived from total cellu-
lar cDNA were constructed. Cellular cDNA was prepared
from several pools of human peripheral blood mononuclear
cells (PBMC) that were stimulated by various treatments
and a cell line able to support viral replication (see Materials
and methods). A flow cytometry assay was developed to
rapidly monitor inhibition of virus in cell culture by the
above GSE libraries. In this cell culture system, HIV-1
replication was determined by measuring the levels of the
viral capsid antigen, p24 Gag, and the attachment receptor
for virions, CD4. Infected cells expressing inhibitory GSEs
would be expected to be phenotypically CD4+, p24.
Because the anti-viral antibody in the selection depends
on synthesis of the Gag capsid protein, this screen could
potentially identify cellular genes that are involved in early
events, such as virion entry into cells, viral DNA synthesis,
and proviral integration, as well as production of viral
transcripts. This screen will not identify genes involved in
the latter part of the viral life cycle including proteolytic
processing of the Gag precursor polypeptide and virion
assembly and release.
As outlined in Fig. 1, a normalized random fragment
library was prepared in a retroviral packaging system and
transferred to CEM-ss cells. Three independent libraries
were constructed from multiple sources of cDNA as
described in Materials and methods and used in three
independent screens. Transduced cells expressing the
vector marker, nerve growth factor receptor (NGFR), were
isolated by flow cytometry. These transduced cells were
infected with saturating levels of HIV-1, and at peak
infection, sorted for the CD4+/p24 phenotype; this phe-
notype is presumed to represent cells protected from
infection by a GSE (Fig. 1B). Genomic DNA was isolated
from the sorted cells, the GSE inserts were amplified by
PCR using vector-derived primers, and subcloned into the
retroviral vector. The selection process was repeated three
times. After the final round of selection, approximately
15000 clones total from all three independent selections
were sequenced, and the homology of the inserts to
cellular genes was assessed by using the BLAST algo-
rithm to query GenBank.
The summary of the genetic screen results is shown
in Fig. 2. Cellular genes identified in this approach
included cytokines, cell surface proteins, and genes with
unknown function. A set of genes that were previously
linked to HIV-1 replication was also isolated in the screen
(Table 1), including the validated therapeutic target,
CXCR4.
Because cell surface proteins are amenable for HIV-1
therapeutic intervention, we decided to further validate their
Fig. 1. Selection of GSEs that block HIV replication. (A) Scheme of GSE selection: (1) transfection of packaging cells with normalized fragment library to
produce library of recombinant retroviruses, (2) transduction of CEM-ss cells with recombinant retroviruses to produce cells expressing library, (3) flow
cytometry sort of transduced cells expressing the selectable marker NGFR, (4) infection of transduced population with HIV-1IIIB, (5) cell sorting of the infected
population for CD4+/p24 representing GSE-protected cells, (6) rescue of inserts by PCR and subcloning into retroviral vector, and (7) sequencing of inserts
and identification of the cognate genes. (B) Representative flow cytometric profile of surface CD4 and intracellular p24 expression of CEM-ss cells containing
vector or library 9 days after infection with HIV-1IIIB. Mock-infected profile shows an uninfected library population. Box indicates the CD4 positive, p24
negative cells that were sorted in the library population. Box is also shown in the mock-infected and vector profile for comparative purposes.
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tional genes were selected; the corresponding GSEs are
listed in Table 2. The known function and tissue expression
of the selected genes are shown in Table 3.Confirmation of inhibitory effect of GSEs
To confirm the inhibitory effect of GSEs derived from
cell surface genes, individual elements were stably trans-
Table 2
Cell surface genes identified by GSEs
Gene Accession no. Library Orientationa Coordinatesb
CXCR4 NM_003467 PBMC1 AS 14–214 (5VUTR/CDS)
CCR4 NM_005508 PBMC1 AS 1505–1566 (3VUTR)
1505–1532 (3VUTR)
CCR7 NM_001838 PBMC1 S 3–127 (5VUTR/CDS)
PBMC2 AS 3–106 (5VUTR/CDS)
1389–1214 (3VUTR)
CD11C NM_000887 PBMC1 AS 4019–4095 (CDS)
PBMC2 AS 1710–1900 (CDS)
4276–4464 (CDS)
CD44 NM_000610 HeLa AS 63–130 (5VUTR)
CD47 NM_001777 HeLa AS 283–375(CDS)
CD68 NM_001251 PBMC2 AS 234–410 (CDS)
273–369 (CDS)
214–372(CDS)
273–372 (CDS)
CD69 NM_001781 PBMC1 S 23–141 (5VUTR/CDS)
CD74 NM_004358 PBMC1 AS 1143–1210 (3VUTR)
1143–1295 (3VUTR)
1155–1287 (3VUTR)
PBMC2 AS 18–238 (CDS)
18–231 (CDS)
18–232 (CDS)
CSF3R NM_000760 PBMC2 AS 55–234 (5VUTR/CDS)
108–234 (5VUTR/CDS)
GABBR1 NM_021905 PBMC2 S 898–1091 (CDS)
954–1123 (CDS)
301–441 (CDS)
TNFR2 NM_001066 PBMC1 AS 2542–2595 (3VUTR)
PBMC2 S 1548–1685 (3VUTR)
a
Fig. 2. Categorization of genes identified by GSEs. Genes identified by
GSEs were placed in functional groups according to currently available
information. Enzymes include all genes that encode for products with
predicted enzymatic activity. Genes with unknown function are those in
which a gene name is assigned, but the function of the gene product is
unknown. Others include ribosomal genes, mitochondrial genes, cell cycle
regulators, transporters, protein maturation proteins, and endocytic proteins.
The total number of genes in this analysis is 800.
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as previously described (Dunn et al., 1999). HIV-1 repli-
cation was monitored and cell viability was assessed. In all
cases, cell proliferation and viability were unaffected by
expression of the GSEs in CEM-ss cells (data not shown).
All cell surface GSEs were shown to inhibit viral replica-
tion to significant levels, ranging from 38.5% for CXCR4
S = sense orientation of GSE; AS = antisense orientation of GSE.
b Data in parentheses indicate GSE location on gene. UTR = untranslated
region; CDS = coding sequence.
Table 1
Genes identified by GSEs that were previously associated with HIV-1
Gene Accession no. Reference
CXCR4 NM_003467 Bleul et al., 1996;
Oberlin et al., 1996
CD44 NM_000610 Lesley and
Hyman, 1998
Cyclin T1 NM_001240 Fujinaga et al., 1998
hnRNP A1 NM_002136 Caputi et al., 1999
Poly A binding
protein
NM_002568 Afonina et al., 1997
DEAD/H9 NM_001357 Li et al., 1999
EF-1a NM_001402 Cimarelli and
Luban, 1999
EF-1y NM_001960 Xiao et al., 1998
IL-8 NM_000584 Lane et al., 2001
Importin beta NM_002265 Truant and Cullen, 1999
HIV-1 TAR binding
protein/RPL3
L22453/NM_000967 Reddy et al., 1995
SLC7A5 NM_003486 Ohgimoto et al., 1995
Nef-associated
factor 1
XM_003683 Fukushi et al., 1999
Cathepsin D NM_001909 El Messaoudi
et al., 2000
TAP1 NM_000593 Reddy et al., 2000
CDC42 NM_001791 Lu et al., 1996
Nef interacting
protein/CCT7
NM_006429 GenBankU83843
PP2A catalytic NM_002715 Faulkner et al., 2003to 94.8% for CD11C (Fig. 3A) compared to cells trans-
fected with vector control.
Isolation of clusters of GSEs represented by overlap-
ping sequences is typically indicative of strong selection
for a particular region of a gene. Such overlapping clusters
were found for CD68, CSF3R, GABBR1, CCR4, CCR7,
and CD74 (Table 2). Our previous testing of GSEs from
more than 150 genes revealed that the isolation of over-
lapping clusters from a given gene always resulted in
functionally active GSEs. Therefore, the genes with over-
lapping clusters, CCR7, CD68, CD74, GABBR1, and
CSF3R (Fig. 3B), were not included in this infection
assay. This set of genes was taken directly to the next
step in confirmation of anti-viral activity using small
interfering RNA (siRNA).
Confirmation of GSEs by small interfering RNA (siRNA)
GSEs can inhibit the function of a gene by several
mechanisms including downmodulation of the gene by
inhibitory RNA or through transdominant peptides. Be-
cause these effects have the potential to be direct or
indirect, it was necessary to confirm the role of the gene
in viral inhibition by an independent method. We used
Fig. 3. Inhibition of virus by GSEs derived from cell surface targets. (A)
Percent inhibition of HIV-1 replication of CEM-ss cell transduced with
GSEs to indicated genes. Bulk populations of CEM-ss cells containing GSEs
or vector were infected with a MOI of 0.001 of HIV-1SF2. Every 3–4 days
for up to 32 days, cells were harvested and stained with anti-p24-FITC (KC-
57) and anti-CD4-PE (L120). Results are presented as percent inhibition of
GSE in comparison to vector at the time point just before peak infection of
the vector control (typically day 21 or 25) and represent at least two
independent experiments. (B) Positions of the isolated GSEs on the mRNA
sequence of selected genes that were not included in infection experiments.
Red indicates sense orientation, while blue indicates antisense orientation.
Table 3
Known function and tissue expression of cell surface genes identified by
GSEs
Gene Function Tissue expression References
CXCR4 Chemokine
receptor;
HIV-1
co-receptor
Widely expressed in
blood and tissue cells
Loetscher
et al., 2000;
Berger
et al., 1999
CCR4 Chemokine
receptor
Peripheral blood
leukocytes, thymocytes,
basophils, monocytes,
macrophages, platelets,
IL-2 activated NK
cells, spleen, brain
Power
et al., 1995
CCR7 Chemokine
receptor
Activated B cells,
T cells, mature
dendritic cells
Yanagihara
et al., 1998;
Yoshida
et al., 1998
CD11C Integrin;
fibrinogen
receptor
Monocytes,
macrophages,
NK cells,
granulocytes,
T cells, B cells
Corbi and
Lopez-Rodriguez,
1997
CD44 Adhesion
molecule;
hyaluronate
receptor
Broad tissue
distribution
Goodison
et al., 1999
CD47 Adhesion
molecule;
thrombospondin
receptor
Broad tissue
distribution
Brown and
Frazier, 2001
CD68 Unknown Monocytes,
macrophages,
activated T cells,
dendritic cells,
neutrophils,
basophils, mast
cells, CD34+ bone
marrow progenitor
cells
Holness and
Simmons, 1993
CD69 Lymphocyte
proliferation
Platelets, activated B
and T cell, NK
cells, neutrophils,
eosinophils, epidermal
Langerhans cells
Marzio
et al., 1999
CD74 MHC class II
processing
B cells, activated
T cells, macrophages,
activated
endothelial and
epithelial cells
Cresswell, 1994
CSF3R Granulocyte
colony-stimulating
factor (G-CSF)
receptor
Bone marrow cells,
placenta, peripheral
blood granulocytes,
endothelial cells
Avalos, 1996
GABBR1 Gamma-
aminobutyric
acid (GABA)
receptor
Brain, heart, small
intestine, uterus,
kidney, lung,
trachea, colon,
stomach, bone
marrow, thymus,
mammary gland
Ong and
Kerr, 2000
TNFR2 TNF-alpha
receptor
Activated B and
T cells,
monocytes,
macrophages,
Langerhans cells
Ryffel and
Mihatsch, 1993
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viral inhibition. Inhibitory effects of siRNA were measured
in HeLa CD4 LTR h-gal cells using a reporter system in
which h-galactosidase is driven by the HIV-1 LTR. This
one step replication assay could potentially identify early
Table 4
siRNA duplex sequences to genes identified by GSEs
Gene Sense strand Antisense strand
CXCR4 CUGGCAUUGUGGGCAAUGGdTdT CCAUUGCCCACAAUGCCAGdTdT
CCR4 GUCCUUCAGGACUGCACCUdTdT AGGUGCAGUCCUGAAGGACdTdT
CCR7 GAGGCUCAAGACCAUGACCdTdT GGUCAUGGUCUUGAGCCUCdTdT
CD11C GCCCUCCCAGGAACACAUAdTdT UAUGUGUUCCUGGGAGGGCdTdT
CD44 UGGCCCAGAUGGAGAAAGCdTdT GCUUUCUCCAUCUGGGCCAdTdT
CD47 ACAAGUCCACUGUCCCCACdTdT GUGGGGACAGUGGACUUGUdTdT
CD68 GCAAUAGCACUGCCACCAGdTdT CUGGUGGCAGUGCUAUUGCdTdT
CD69 GUUCCUGUCCUGUGUGCUGdTdT CAGCACACAGGACAGGAACdTdT
CD74 ACUGACAGUCACCUCCCAGdTdT CUGGGAGGUGACUGUCAGUdTdT
CSF3R CCACACUCAGGCCUUUCUCdTdT GAGAAAGGCCUGAGUGUGGdTdT
GABBR1 UAUUGGUUCCUGGGCUGCUdTdT AGCAGCCCAGGAACCAAUAdTdT
TNFR2 CAGAACCGCAUCUGCACCUdTdT AGGUGCAGAUGCGGUUCUGdTdT
Lamin A/C AACUGGACUUCCAGAAGAACAdTdT UGUUCUUCUGGAAGUCCAGUUdTdT
S.J. Dunn et al. / Virology 321 (2004) 260–273 265events in the viral life cycle including viral entry and early
gene expression, reflecting Tat-mediated transactivation of
the HIV-1 LTR. HeLa CD4 LTR h-gal cells were trans-
fected with 19–21-nucleotide siRNA duplexes derived
from various cellular targets (Table 4) followed by infec-
tion with optimized amounts of HIV-1. At 48 h postinfec-
tion, antiviral activity was assessed by lysing cells and
measuring the amount of h-gal produced. All measure-
ments of inhibition were made in comparison to control
cells transfected with lamin A/C siRNA. Transfection of
siRNA to all surface molecules resulted in fully viable
cells (data not shown). In agreement with previous reports
(Novina et al., 2002), CXCR4-specific siRNA inhibited
HIV-1 replication. As shown in Fig. 4, 38–86% inhibition
of h-gal activity was observed with the siRNA derived
from various cell surface targets, with the exception of
CD69 (Fig. 4A). The GSE to the T cell specific antigen,
CD69, was shown to be effective in CEM-ss cells, but
because CD69 is not expressed at the mRNA or protein
level in HeLa CD4 LTR h-gal cells, the role of this gene
could not be adequately assessed in this system.
Next, the cell surface expression of select genes,
CXCR4, CD47, and CD44, was measured to correlate
the siRNA inhibitory effect to protein expression levels.
CXCR4 siRNA was transfected as above and assayed 48
h after transfection using a CXCR4-specific monoclonal
antibody. Results were compared to cells transfected with
the control Lamin A/C siRNA. CXCR4 siRNA specifi-
cally downmodulated surface expression of CXCR4 as
detected by FACS analysis (Fig. 4B), with no effect on
CD4 expression (data not shown). Similarly, CD47,
CD44, CSF3R, and TNFR2 cell surface expression was
downmodulated in cells transfected with CD47, CD44,
CSFR, and TNFR2 siRNA, respectively (Fig. 4B). In the
case of CSF3R, the downmodulation is slight, but repro-
ducible. No effect was observed in these cells on CXCR4
or CD4 expression (data not shown). These results
indicate that the selected siRNAs specifically downregu-
late the corresponding targets and subsequently effect
gene function.Comparable inhibition of viral replication by siRNAs
derived from target genes and known HIV-1 inhibitors
To determine the potency of siRNAs derived from
various cell surface targets, we compared the inhibitory
effects obtained with the siRNA to known HIV-1 inhibitors.
The nucleoside analog AZT is a competitive inhibitor of
viral reverse transcriptase (Furman and Barry, 1988), and
the entry inhibitor T20 is a 36 amino acid peptide that
blocks fusion of the virus and host cell membranes by
binding to gp41 (Kilby et al., 1998). HeLa CD4 LTR h-
gal cells were incubated with AZT or T20 for 3 h followed
by infection with HIV-1. Analysis of the infections 48 h later
showed a dose response for each antiviral drug (Fig. 4C).
AZT at concentrations of 1 and 10 AM inhibited replication
by 83% and 90%, respectively. The levels of inhibition with
T20 increased from 38.5% for 1 nM to 91% for 200 nM.
Similar levels of inhibition were observed with the various
siRNAs. These data indicate that inhibitors against these
host cell targets could provide the basis of potent anti-HIV-1
drugs.
Inhibition at early stage of HIV-1 replication measured by
viral DNA synthesis assay
To understand whether cell surface genes, identified
through the functional genetic screen, were important in
early events of the HIV-1 life cycle, the effect of target
siRNAs on viral DNA synthesis was determined. Known
inhibitors of early steps in viral replication, T20 (inhibitor of
gp41 and virion fusion-entry) and AZT (inhibitor of reverse
transcriptase and viral DNA synthesis) as well as CXCR4
siRNA, were used as controls. As shown in Fig. 5, viral
DNA synthesis was inhibited in CXCR4 siRNA-transfected
cells as well as in T20- and AZT-treated cells. Additionally,
eight of the surface genes (CCR4, CCR7, CD11C, CD44,
CD47, CD68 CD74, TNFR2) showed inhibition of viral
DNA synthesis of more than 40% compared to cells trans-
fected with the control Lamin A/C siRNA. GABBR1
demonstrated minimal inhibition of 30%, whereas CSF3R
S.J. Dunn et al. / Virology 321 (2004) 260–273266
Fig. 5. Viral DNA synthesis in cells transfected with siRNA directed
towards cell surface genes. HeLa CD4 LTR h-gal cells were transfected
with 100 nM siRNA followed by infection with a MOI of 0.5 of HIV-1NL4-3
24 h later. AZT (1 AM) and T20 (100 nM) were preincubated with cells for
3 h before infection. At 48 h postinfection, cells were lysed and cellular
DNAwas extracted. Real-time PCR was used to determine copy number of
HIV-1 DNA. Results are presented as percent inhibition of cells containing
siRNA to indicated gene or drug in comparison to cells containing Lamin
A/C siRNA and represent duplicates run in at least two independent
experiments.
S.J. Dunn et al. / Virology 321 (2004) 260–273 267siRNA-transfected cells did not inhibit viral DNA synthesis.
This indicates that CSF3R may play a role in post-viral
DNA synthesis events.Discussion
Most of the effort for HIV-1 therapeutics has been
focused on targets derived from the viral genome such as
reverse transcriptase and protease, rather than essential host
cell targets. Although drugs that block viral protein function
are selective and consequently less toxic, viral resistance has
been exhibited by several drugs due to the high rate of viral
mutation and selection of resistant viral variants in the drug-
treated individual. As for other disease indications where
most drugs in clinical use act on cellular targets, host
proteins could be targeted for the development of effective
therapeutics against HIV-1 as well. Whether the virus will
become resistant to cellular-based therapeutics has yet to be
determined. It is less likely, however, that the virus will
overcome complex interactions with host proteins required
for replication. Individual differences in a gene such as
deletions or mutations could potentially play a factor inFig. 4. Transfection of cells with siRNAs to cell surface genes. (A) Percent inhib
siRNA directed towards the indicate genes. Cells were transfected with 100 nM s
48 h postinfection, cells were lysed and h-gal was measured. Results are prese
comparison to cells containing Lamin A/C siRNA. All transfections and infections
(B) HeLa CD4 LTR h-gal cells were transfected with 100 nM of siRNA directed to
were stained 48 h later with PE-conjugated CXCR4 monoclonal antibody (12G5) a
twice (second transfection at 72 h following the initial transfection) with siRNA to
protein with PE-conjugated CD47 mAb (B6H12), CD44 mAb (515), CSF3R m
include all transfected cells stained with IgG1-PE. Overlapping histograms from
drugs in CD4 LTR h-gal assay. Increasing concentrations of AZT and T20 were
a 3-h incubation, cells were infected with HIV-1NL4-3. At 48 h postinfection, ce
inhibition of cells containing increasing concentrations of AZT or T20 in compsusceptibility or effectiveness of an inhibitor targeting a
cellular factor. Several inhibitors against the host receptor
and co-receptors for virus (i.e., CD4, CCR5 or CXCR4) that
block HIV-1 entry into cells are currently in clinical devel-
opment. Our study describes the identification of cellular
genes essential for HIV-1 replication that could be used as
drug targets for antiviral therapeutics.
The genetic screen, originally developed to isolate ge-
netic inhibitors of HIV-1 replication (Dunn et al., 1999), was
used to select GSEs derived from cellular genes that are
crucial for viral replication. The present study was designed
to focus on the identification of cell surface molecules for
the development of HIV-1 therapeutics. Expression of cell
surface CD4 and viral p24 Gag were used as markers
because HIV-1 replication is characterized by accumulation
of intracellular p24 Gag and downmodulation of CD4
surface expression. Expression of GSEs interfering with
productive infection should result in the enrichment of
CD4+/p24 cells. The antibody against p24 Gag recognizes
both the Gag precursor polypeptide and forms of this viral
protein, including p24 Gag, that are processed by viral
protease. Therefore, the assay was set to identify GSEs that
could potentially act on a wide range of steps in the HIV
replication cycle from viral entry to translation of Gag.
Genes involved in steps from Gag proteolytic processing to
virus egress, such as components of the vesicular protein
sorting machinery including Tsg101 and Vps4 (Garrus et al.,
2001), were not isolated in the screen. The use of a retroviral
packaging system allows only a single element to be
transferred and expressed in a cell. As a result, phenotypes
requiring the simultaneous expression of two or more genes
to inhibit replication would not be selected.
Although many of the cellular genes reported here
represent the first link to HIV-1, some have been previously
implicated in viral infection. The isolation of these genes
validates our approach to identify cellular targets that are
critical for HIV-1 replication. These genes belong to a
variety of categories as described in Fig. 2. These include
cell surface genes (CXCR4 and CD44), enzymes (PP2A),
cytokines (IL-8), transcriptional machinery (EF-1a, EF-1y,
Poly A binding protein, cyclin T1), splicing factors (hnRNP
A1), signaling molecules (CDC42), genes with unknown
function (Nef-associated factor), and other functions such as
various transporter molecules (SLC7A5, TAP1, importin h).ition of HIV-1 replication of HeLa CD4 LTR h-gal cells transfected with
iRNA followed by infection with a MOI of 5 of HIV-1NL4-3 24 h later. At
nted as percent inhibition of cells containing siRNA to indicate gene in
were done in triplicate and represent at least two independent experiments.
wards the target gene or Lamin A/C. Cells transfected with CXCR-4 siRNA
nd analyzed for CXCR4 expression using a FACSort. Cells were transfected
CD47, CD44, CSF3R, or TNFR2 and analyzed for expression of the target
Ab (LMM741), or TNFR2 mAb (4D1B10), respectively. Isotype controls
a representative experiment are depicted. (C) Effect of HIV-1 antiviral
added to HeLa CD4 LTR h-gal cells at the indicated concentrations. After
lls were lysed and h-gal was measured. Results are presented as percent
arison to cells without antiviral drugs.
S.J. Dunn et al. / Virology 321 (2004) 260–273268Isolation of GSEs to CXCR4, with further demonstration
that the CXCR4 GSE and siRNA could inhibit viral
replication in CEM-ss cell and in HeLa CD4 LTR h-gal
cells, respectively, indicated that the screen could detect
genes involved in the entry of the virus into the cell. Viral
entry is a multistep process involving viral attachment, CD4
binding, co-receptor binding, and fusion of the viral and
cellular membranes. The attachment step has been specu-
lated to constitute the rate-limiting step in virus entry
(O’Doherty et al., 2000). Cell surface molecules can either
directly or indirectly enhance this process by increasing
HIV-1 binding or infectivity (Ugolini et al., 1999). This
supports the notion that cellular adhesion molecules can
significantly influence initial early events in the virus–cell
interaction such as viral attachment to cells and the gp120–
CD4–co-receptor interaction.
In addition to CXCR4, the GSE screen identified one
other cell surface gene previously implicated in HIV-1
infection, CD44. CD44 was shown to increase interaction
of virions with cells, enhance viral infectivity, and extend
the host cell range of the virus (Hioe et al., 1998). CD44
antibodies can block infection of monocytes by some strains
of HIV-1 (Rivadeneira et al., 1995). Additionally, a recent
report has suggested that CD44 is involved as an auxiliary
receptor for RANTES-mediated activation signals, and
interference of CD44 leads to inhibition of HIV-1 infectivity
enhancement by RANTES (Roscic-Mrkic et al., 2003).
The rest of the cell surface genes that were identified in
the screen either have no previous link to HIV-1 (CD68,
CD74, GABBR1, CSF3R, and CD47) or are indirectly
associated with the virus (CD69, CD11C, TNFR2, CCR4,
and CCR7). Although several reports indicated increases in
expression levels of CD69, CD11C, and TNFR2 during
HIV-1 infection (Blazquez et al., 1999; Rimaniol et al.,
1997; Ryo et al., 2000; Wasserman et al., 1994), no
functional requirement for these genes was established for
viral replication. CCR4, one of many co-receptors shown to
act as a co-receptor for HIV-2 (Owen et al., 1998), has low
affinity for HIV-1 and is not utilized in the presence of
CXCR4 (Agrawal et al., 2002). Expression, however, of
human CCR4 on mouse cells lacking co-receptors (CCR5
and CXCR4) has been shown to allow for entry of HIV-1
(Agrawal et al., 2002). The inhibition of replication caused
by CCR4 interference indicates a possible alternative role
for this molecule. CCR7 signaling by associated chemokine
binding was shown to have a strong positive effect on viral
replication by enhancing activity of the HIV-1 LTR (Nagira
et al., 1999). The block in replication before viral DNA
synthesis caused by CCR7 siRNA interference also suggests
an alternative role for this molecule.
The example of the CXCR4 co-receptor demonstrates
and validates our approach for assigning critical roles for
new cell targets in the HIV life cycle. The GSEs and
siRNAs derived from many of the surface genes were
more potent than those derived from CXCR4. This may
reflect an increased importance of the other genes in viralreplication or a potency factor of the genetic inhibitors.
Alternatively, the high degree of downmodulation resulting
from the CXCR4 siRNA may indicate that fewer mole-
cules of surface CXCR4 may be needed for productive
infection.
Surface molecules were effectively identified and con-
firmed as important in viral replication using different
infection conditions, cell types, and assays. For each cell
type and assay, viral dose and other experimental conditions
were specifically optimized. In CEM-ss cells, GSEs were
stably expressed, thereby allowing for multiple rounds of
viral infection. Therefore, MOI changes in the input virus
(HIV-1SF2) made little difference in the percent of viral
inhibition as such. However, the transient nature of the
siRNA methodology in HeLa CD4 LTR h-gal cells neces-
sitated the need for a one-step infection assay. The use of
HIV-1NL4-3, produced from a plasmid, allowed for an MOI
of sufficient magnitude to achieve a relevant difference
between infected and uninfected cells. On the other hand,
sensitivity of the viral entry assay as monitored by produc-
tion of HIV DNA by real-time PCR in the same cell line
(HeLa CD4 LTR h-gal) allowed for a 10-fold reduction in
the input virus (HIV-1NL4-3). Increased amounts of HIV-
1NL4-3 provided similar results.
The use of siRNA allowed for confirmation of the hits
obtained with the GSEs. Although GSEs are comprised of
sense and antisense elements, siRNA action could be
comparable to antisense GSEs. GSEs that encode peptides
could act in a transdominant fashion, either directly inhibit-
ing the cognate gene or indirectly affecting an interactor of
the cognate gene product. Combining the selection power of
GSX with siRNA technology resulted in a rapid approach
for validating gene function. Comparison of siRNA-trans-
fected cells to AZT- and T20-treated cells served to indicate
that therapeutic targeting of the validated genes could result
in efficacy levels similar to that of antiviral drugs already in
clinical use for treatment of AIDS. Thus, these cell surface
targets provide the basis for antiviral therapeutics that could
not only reduce virus load in infected individuals but also
prevent transmission of virus among individuals (i.e., top-
ical virocides). Extension of this analysis to primary cells,
including T cells and monocytes–macrophages, as well as
different types of viruses, including R5 and primary isolates,
will enable us to determine whether these surface molecules
play a role in entry of the virus into various hematopoietic
cells during viral exposure and infection.Materials and methods
Cells, virus, antiviral agents, and plasmids
CEM-ss (NIAID AIDS Research and Reference Reagent
Program) were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (FBS) at 37 jC and
5% CO2. HeLa CD4+LTR-h-gal cells (NIAID AIDS Re-
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Manassas, VA), and the amphotropic virus packaging cell
line, Phoenix-ampho (Dr. G. Nolan, Stanford University),
were maintained in DMEM medium supplemented with
10% FBS at 37 jC and 5% CO2. Viral stocks of HIV-1SF2
and HIV-1IIIB were prepared as previously reported (Dunn et
al., 1999). HIV-1NL4-3 was prepared by transfection of 293T
cells in 75-cm2 flasks with pNL4-3 proviral DNA (25 Ag).
At 48 h after transfection, the virus-containing supernatant
was collected and clarified by low speed centrifugation.
Samples of virus in cell culture medium were stored at 70
jC. AZT was purchased from Sigma (St. Louis, MO) and
T20 from American Peptide (Sunnyvale, CA). The retroviral
vectors LNCX and LXSN (Miller and Rosman, 1989) were
obtained from Dr. D. Miller (Fred Hutchinson Cancer
Center). LNgfrM and LXSNgfr were constructed by replac-
ing the neomycin resistance gene with a truncated low-
affinity nerve growth factor (NGFR) gene. LXEMCVNgfr
was constructed by inserting the encephalomyocarditis virus
(EMCV) internal ribosomal entry site isolated from the
plasmid, pCITE (Amersham, Arlington Heights, IL), into
the EcoRI–NcoI site of LXSNgfr.
Cell staining for flow cytometry
For CD4, NGFR, or CXCR4 staining, cells were washed
twice with wash buffer (5% FBS, 1.5% BSA, 0.0055%
EDTA), blocked with 5% normal mouse serum, followed
by the addition of phycoerythrin (PE)-conjugated monoclo-
nal antibodies. Following a 30-min incubation, the cells were
washed twice and analyzed or sorted by flow cytometry. The
PE-conjugated monoclonal antibodies used included CD4
clones L120 (BD Immunocytometry Systems, San Jose, CA)
or Q4120 (Sigma), NGFR clone 20.4 (ATCC), CXCR4 clone
12G5 (BD Pharmingen, San Diego, CA), CD47 clone
B6H12 (BD Pharmingen), CSF3R clone LMM741 (BD
Pharmingen), CD44 clone 515 (BD Pharmingen), and
TNFR2 clone 4D1B10 (Caltag, Burlingame, CA).
Intracellular p24 analysis was performed as previously
described (Dunn et al., 1999). Briefly, cells were stained for
CD4 (L120) as above, resuspended in 100 Al PBS, and then
fixed by adding 1 ml of PermeaFix (Ortho Diagnostics;
Raritan, NJ). After a 40-min incubation at room tempera-
ture, the cells were pelleted, washed once, then blocked and
incubated for 30 min with FITC-conjugated anti-p24 (KC-
57; Coulter, Hialeah, FL). Cells were then washed twice and
analyzed or sorted by flow cytometry.
Generation of Random Fragment Libraries
Construction of the random-fragmented library from
normalized HeLa cell cDNA in LNCX was performed as
described (Gudkov and Roninson, 1996). The library was
cloned initially in LNCX, but was cloned into LNgfrM after
the first round of selection. The 5V adaptor sequence for the
library contained three ATGs (5V-GAATTCAAGCTTATG-GATGGATGG-3V), and the 3V adaptor contained three stop
codons (5V-GGATCCATCGATTCACTCACTCA-3V). The
library contained approximately 50 million clones.
The PBMC1-normalized random fragment library was
constructed using cDNA from peripheral blood mononu-
clear cells (PBMC). Buffy coats were obtained from four
healthy donors, and PBMCs were purified by Ficoll
gradient centrifugation followed by stimulation with PHA
(1 Ag/ml). Cells were removed 5, 10, and 24 h after the
addition of PHA, and total RNA was isolated by Trizol
extraction and then pooled. Polyadenylated mRNA was
purified from total RNA with random primers using the
Gibco Superscript Choice system for cDNA synthesis
(Gibco BRL, Rockville, MD). The cDNA was normalized
using the PCR-Select cDNA Subtraction kit (Clontech,
Palo Alto, CA) based on the suppression subtractive
hybridization methods of Diatchenko et al. (1996). The
primers for the normalization were 5V-TAGGGCTC-
GAGCCGCCACCATG-3V and 5V-ATCCCTGCAGGT-
CACTCACTCA-3V. The normalized random fragments
were digested with XhoI and Sse8387I, purified on quick
spin columns (Qiagen, Valencia, CA), and ligated into the
SseI–XhoI site of LXEMCVNgfr. The ligation mix was
then transformed into competent bacterial cells. The total
plasmid was purified from approximately 50 million
clones.
PBMC2 is a normalized random fragment library pre-
pared from Ficoll gradient purified PBMC representing 60
healthy donors and consisting of different populations (total
unstimulated PBMC, CD3/CD28 stimulated PBMC, puri-
fied monocytes and macrophages, and purified memory and
naive T cells). Unstimulated total PBMCs were directly
harvested following Ficoll purification. CD3/CD28-stimu-
lated PBMCs were generated by adding CD3 and CD28
antibodies (CD3/CD28 stimulation) and harvesting after 6
days in culture. Purified monocytes and macrophages were
generated by sorting PBMC for CD14, culturing on glass
plates, and harvesting adherent cells at days 2, 4–5, and
10–12. Memory and naive cells were generated by sorting
PBMC using CD4, CD45RA, and CD62L antibodies into
memory (CD4+, CD45RA, and CD62L+) and naive
(CD4+, CD45RA+, and CD62L+) T cell populations fol-
lowed by stimulation with CD3/CD28 for 5–7 days. Total
RNAwas extracted from all harvested populations using the
RNeasy Maxi kit (Qiagen) and pooled. The normalization
strategy was based on self-subtraction at the RNA level.
Total RNA was partially purified with oligotex (Qiagen) to
produce polyadenylated mRNA. The oligotex-primed poly-
adenylated mRNA was then used as template to synthesize
oligotex-bead linked first-strand cDNA. The oligotex bead
linked first-strand cDNA was used as a driver to subtract
abundant gene populations from PBMC total RNA. Nor-
malization was performed with a 1:2 ratio of total RNA to
cDNA driver at 37 jC for 10 min. The abundant and rare
genes were brought to within 2.5 orders of magnitude as
measured by real time PCR. Messenger RNA was then
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fragmented with weak alkaline-sodium carbonate at 60 jC
for 10 min. The fragmented mRNA was the template for
cDNA synthesis (Ominiscript kit, Qiagen) with primers that
included six random nucleotides linked to a NotI or FseI site
and a sequence for PCR priming, 5V-pGCTATGACCAT-
GATTACGCCAGGCCGGCCNNNNNN-3V and 5V-
pGTAATACGACTCACTATAGGGCGGCCGCNNNNNN-
3V. Following cDNA synthesis, the fragments were PCR
amplified using the following primers, 5V-GCTATGAC-
CATGATTACGCCA-3V and 5V-GTAATACGACTCACTA-
TAGGGC-3V. The fragments were digested with NotI and
FseI and those in the size range of 100–600 bp were
fractionated using 2% agarose gel, eluted, and ligated into
pLXEMCVNgfr. The ligation mixture was electroporated
into DH10B competent cells, generating greater than 100
million transformants.
Preparation of recombinant retrovirus
Phoenix-ampho packaging cells were transfected with
retroviral plasmid DNA (library or individual GSEs) using a
standard calcium phosphate method and the filtered retro-
viral supernatants were used to transduce the target cells as
previously described (Dunn et al., 1999).
HIV-1 screen and selection for GSEs
Transduced CEM-ss cells (library or vector) were
infected with HIV-1IIIB at a TCID50 of 3000 per 10
6 cells
(MOI of 0.003) and the p24 negative, CD4 positive popu-
lation was sorted 9–10 days postinfection. Genomic DNA
purification, insert amplification, subcloning, and sequenc-
ing were performed as previously described (Dunn et al.,
1999). Three rounds of selection were performed for each
library. For HeLa, a total of 15  106 cells were infected in
each of the first two rounds of selection and 5  106 cells in
the third round. For PBMC1, 30  106 cells were infected in
the first round, followed by 5  106 in each subsequent
round. For PBMC2, 300  106 cells were infected in the
first round, followed by 15  106 and 5  106 in the second
and third round, respectively.
HIV-1 infection of CEM-ss cells
Before infection, all cells were stained for the presence of
CD4. For bulk populations of cells containing GSEs, growth
rates as compared to the vector control were assessed by cell
counting using trypan blue exclusion. Cells (1  106) were
incubated at 37 jC for 30 min in the presence of polybrene
(Sigma; 4 Ag/ml), and then infected with a MOI of 0.001 of
HIV-1SF2 in a 1-ml volume for 2 h at 37 jC. Cells were
cultured in a total volume of 5 ml (2  105 cells/ml) of
media. Samples were withdrawn every 3–4 days for intra-
cellular p24 Gag analysis, and cells were passaged to 2 
105 cells/ml in fresh media.RNAi studies
Duplexes of siRNA were designed according to the
guidelines established by the Tuschl lab (http://
www.rockefeller.edu/labheads/tuschl/sirna.html). Nucleo-
tide RNA duplexes (19–21) with an overhang of two
nucleotides on the 3V termini were synthesized (Proligo,
Boulder, CO) for each of the targets. The sequences of
the siRNA are shown in Table 4.
HeLa CD4 LTR h-gal cells were seeded at a density of
25000 cells per well of a 12-well plate. After an overnight
incubation, cells were transfected using standard protocols
with 100 nM of siRNA using the Oligofectamine reagent
(Invitrogen, Carlsbad, CA). At 24 h post-transfection, cells
in each well were infected with an MOI of 5 of HIV-1NL4-3,
an amount of virus found to give optimal readout in the
assay. Forty-eight hours postinfection, cells were lysed and
the relative amount of h-galactosidase was determined using
a h-galactosidase detection kit according to the manufac-
turers directions (Galacto-Light Plus System; Applied Bio-
systems, Foster City, CA). Measurements of luminescence
were made in a luminometer (Tropix Microplate Luminom-
eter TR717; Applied Biosystems). All readings were com-
pared to negative control cells transfected with Lamin A/C
siRNA. Duplicate plates that were uninfected were used to
determine cell viability using a WST-1 assay (Roche Diag-
nostics, Indianapolis, IN).
Specificity of the siRNA-induced downregulation of the
target gene was assessed by antibody staining of the cells.
The siRNAwas transfected into HeLa CD4 LTR h-gal cells
as described above, followed by staining with the
corresponding cell surface antibody 48 h later. Alternative-
ly, cells were transfected a second time with the siRNA
followed by antibody staining 48 h after the second
transfection.
Viral DNA synthesis
HeLa CD4 LTR h-gal cells were transfected with siRNA
and infected with an MOI of 0.5 of HIV-1NL4-3 24 h post-
transfection This amount of virus was optimized to give
optimal readout. Cells were lysed 48 h after infection with
HIV-1NL4-3. Total cellular DNA was extracted and purified
using the Blood and Tissue Extraction Kit (Qiagen). Real-
time PCR of the p24 gag gene of HIV-1 was performed as
described by Desire et al. (2002). HIV-1 DNA was quanti-
fied by comparison to single copy gene, CCR5, in the total
cellular DNA and normalized to obtain proviral DNA copies
per million cells.Acknowledgments
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